Abstract:Background Neuropilin - 2 ( NRP2) is a high-affinity kinase-deficient receptor for vascular endothelial growth factor ( VEGF) and semaphorin 3F. We investigated its function in human colorectal cancers.Methods Immunohistochemistry and immunoblotting were used to assess NRP2 expression levels in colorectal tumors and colorectal cancer cell lines, respectively. HCT-116 colorectal cancer cells stably transfected with short hairpin RNA ( shRNAs) against NRP2 or control shRNAs were assayed for proliferation by the tetrazolium salt 3-( 4,5-dimethylthiazol-2-yl)- 2,5- diphenyltetrazolium bromide ( MTT) assay and for activation of the VEGFR1 pathway by immuno blotting. Soft agar assays, Annexin V staining, and Boyden chamber assays were used to examine anchorage-independent growth, apoptosis in response to hypoxia, and cell migration/ invasion, respectively, in HCT-116 transfectants. Tumor growth and metastasis were analyzed in mice ( groups of 10) injected with shRNA-expressing HCT-116 cells. The effect of in vivo targeting of NRP2 by small interfering RNA ( siRNA) on the growth of hepatic colorectal tumors derived from luciferase-expressing HCT-116 cells was assessed by measuring changes in bioluminescence and final tumor volumes. All statistical tests were two-sided.Results NRP2 expression was substantially higher in tumors than in adjacent mucosa. HCT-116 transfectants with reduced NRP2 levels had reduced VEGFR1 signaling, but proliferation was unchanged. Anchorage-independent growth, survival under hypoxic conditions, and motility/ invasiveness were also reduced. In vivo, HCT-116 transfectants with reduced NRP2 demonstrated decreased tumor growth, fewer metastases, and increased apoptosis compared with control cells. Hepatic colorectal tumors in mice treated with NRP2 siRNAs were statistically significantly smaller than those in mice treated with control siRNAs ( at 28 days after implantation, mean control siRNAs = 420 mm(3), mean NRP2 siRNAs = 36 mm(3), NRP2 vs control: difference = 385 mm(3), 95% confidence interval = 174 mm(3) to 595 mm(3), P =.005).Conclusion NRP2 on colorectal carcinoma cells is important for tumor growth and is a potential therapeutic target in human cancers where it is expressed.

Construction of Novel Procoagulant Protein Targeting Neuropilin-1 on Tumour Vasculature for Tumour Embolization Therapy

Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels.

Design and Construction of a Magnetic Targeting Pro-Coagulant Protein for Embolic Therapy of Solid Tumors

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

Construction And Characterization Of A Truncated Tissue Factor-Coagulation-Based Composite System For Selective Thrombosis In Tumor Blood Vessels

Egfp-Egf1 Protein-Conjugated Peg-Pla Nanoparticles for Tissue Factor Targeted Drug Delivery

Comparison of Three Different Targeted Tissue Factor Fusion Proteins for Inducing Tumor Vessel Thrombosis.

A Recombined Fusion Protein SP5.2/tTF Induce Thrombosis in Tumor Blood Vessel.

Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction

Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma

A Tissue Factor Targeted Nanomedical System for Thrombi-Specific Drug Delivery.

Ph-Responsive Liposomes Loaded with Targeting Procoagulant Proteins As Potential Embolic Agents for Solid Tumor-Targeted Therapy.

NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6C<SUP>low</SUP> Monocytes/Macrophages Differentiation to Accelerate Thrombolysis

Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver

Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)3 -tTF

Targeting neuropilin-1 interactions is a promising anti-tumor strategy

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

The Synergistic Blood-Vessel-embolization of Coagulation Fusion Protein with Temperature Sensitive Nanogels in Interventional Therapies on Hepatocellular Carcinoma

Effect of Egf1 Peptides in Directing Nanoparticles to Thrombi

Combination of Tumour-Infarction Therapy and Chemotherapy Via the Co-Delivery of Doxorubicin and Thrombin Encapsulated in Tumour-Targeted Nanoparticles

Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.